- -
-
Ključne reči:
-
Sažetak
-
Reference
1. Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E. Single-dose psilocybin for a treatment-resistant episode of major depression. The New England Journal of Medicine, 2022;387(18):1637-1648.
2. Marwaha S, Palmer E, Suppes T, Cons E, Young AH, Upthegrove R. Novel and emerging treatments for major depression. The Lancet, 2023;401(10371):141-153.
3. Hsieh MH. Electroconvulsive therapy for treatment-resistant depression. Prog Brain Res. 2023;281:69-90.
4. Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Long-term safety of ketamine and esketamine in treatment of depression. Expert Opinion on Drug Safety, 2022;21(6):777-787.
5. Li Y, Liu H. Clinical powers of aminoacyl tRNA synthetase complex interacting multifunctional Protein 1 (AIMP1) for head-neck squamous cell carcinoma. Cancer Biomarkers: Section A of Disease Markers, 2022;34(3):359-374.
6. Zheng CM, Piao XM, Byun YJ, Song SJ, Kim SK, Moon SK, Choi YH, Kang HW, Kim WT, Kim YJ, Lee SC, Kim WJ, Yun SJ. Study on the use of nanostring nCounter to analyze RNA extracted from formalin-fixed-paraffin-embedded and fresh frozen bladder cancer tissues. Cancer Genetics, 2022;268-269:137-143.
7. Jin Z, Zhang W, Liu H, Ding A, Lin Y, Wu SX, Lin J. Potential therapeutic application of local anesthetics in cancer treatment. Recent Patents on Anti-Cancer Drug Discovery, 2022;17(4):326-342.
8. Frank P, Batty GD, Pentti J, Jokela M, Poole L, Ervasti J, Vahtera J, Lewis G, Steptoe A, Kivimäki M. Association between depression and physical conditions requiring hospitalization. JAMA Psychiatry, 2023;80(7):690-699.
9. Indirli R, Lanzi V, Arosio M, Mantovani G, Ferrante E. The association of hypogonadism with depression and its treatments. Frontiers in Endocrinology, 2023;14:1198437(1-14).
10. Steffens DC. Treatment-resistant depression in older adults. The New England Journal of Medicine, 2024;390(7):630-639.
11. Lorenzo EC, Kuchel GA, Kuo CL, Moffitt TE, Diniz BS. Major depression and the biological hallmarks of aging. Ageing Research Reviews, 2023;83:101805(1-27).
12. Mirchandaney R, Barete R, Asarnow LD. Moderators of cognitive behavioral treatment for insomnia on depression and anxiety outcomes. Current Psychiatry Reports, 2022;24(2):121-128.
13. Heissel A, Heinen D, Brokmeier LL, Skarabis N, Kangas M, Vancampfort D, Stubbs B, Firth J, Ward PB, Rosenbaum S, Hallgren M, Schuch F. Exercise as medicine for depressive symptoms? A systematic review and meta-analysis with meta-regression. British Journal of Sports Medicine 57(Pt A):bjsports-2022-106282, 2023;57(16):1049-1057.
14. Kofod J, Elfving B, Nielsen EH, Mors O, Köhler-Forsberg O. Depression and inflammation: correlation between changes in inflammatory markers with antidepressant response and long-term prognosis. European Neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 2022;54:116-125.
15. Runia N, Yücel DE, Lok A, de Jong K, Denys DAJP, van Wingen GA, Bergfeld IO. The neurobiology of treatment-resistant depression: A systematic review of neuroimaging studies. Neuroscience and Biobehavioral Reviews, 2022;132:433-448.
16. Hagatulah N, Bränn E, Oberg AS, Valdimarsdóttir UA, Shen Q, Lu D. Perinatal depression and risk of mortality: nationwide, register based study in Sweden. BMJ, 2024;384:e075462(1-10).
17. Vita G, Compri B, Matcham F, Barbui C, Ostuzzi G. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2023 Mar 31;3(3):CD011006(1-80).
18. Mitra A, Raichle ME, Geoly AD, Kratter IH, Williams NR. Targeted neurostimulation reverses a spatiotemporal biomarker of treatment-resistant depression. Proceedings of the National Academy of Sciences of the United States of America, 2023;120(21):e2218958120(1-6).
19. Siddiqi SH, Kandala S, Hacker CD, Bouchard H, Leuthardt EC, Corbetta M, Morey RA, Brody DL. Precision functional MRI mapping reveals distinct connectivity patterns for depression associated with traumatic brain injury. Science Translational Medicine, 2023;15(703):eabn0441(1-11).
20. Maruani J, Boiret C, Leseur J, Romier A, Bazin B, Stern E, Lejoyeux M, Geoffroy PA. Major depressive episode with insomnia and excessive daytime sleepiness: a more homogeneous and severe subtype of depression. Psychiatry Research, 2023;330:115603(1-8).
21. Currie JM, Mercer M, Michael R, Pichardo D. New caregiver diagnoses of severe depression and child asthma controller medication adherence. International Journal of Environmental Research and Public Health, 2023;20(11):5986(1-10).
22. Zwolińska W, Skibinska M, Słopień A, Dmitrzak-Węglarz M. ProBDNF as an indicator of improvement among women with depressive episodes. Metabolites, 2022;12(4):358(1-9).
23. Sochal M, Ditmer M, Binienda A, Gabryelska A, Białasiewicz P, Talar-Wojnarowska R, Fichna J, Małecka-Wojciesko E. Relation between selected sleep parameters, depression, anti-tumor necrosis factor therapy, and the brain-derived neurotrophic factor pathway in inflammatory bowel disease. Metabolites, 2023;13(3):450(1-18).
24. Min X, Wang G, Cui Y, Meng P, Hu X, Liu S, Wang Y. Association between inflammatory cytokines and symptoms of major depressive disorder in adults. Frontiers in Immunology, 2023;14:1110775(1-8).
2. Marwaha S, Palmer E, Suppes T, Cons E, Young AH, Upthegrove R. Novel and emerging treatments for major depression. The Lancet, 2023;401(10371):141-153.
3. Hsieh MH. Electroconvulsive therapy for treatment-resistant depression. Prog Brain Res. 2023;281:69-90.
4. Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Long-term safety of ketamine and esketamine in treatment of depression. Expert Opinion on Drug Safety, 2022;21(6):777-787.
5. Li Y, Liu H. Clinical powers of aminoacyl tRNA synthetase complex interacting multifunctional Protein 1 (AIMP1) for head-neck squamous cell carcinoma. Cancer Biomarkers: Section A of Disease Markers, 2022;34(3):359-374.
6. Zheng CM, Piao XM, Byun YJ, Song SJ, Kim SK, Moon SK, Choi YH, Kang HW, Kim WT, Kim YJ, Lee SC, Kim WJ, Yun SJ. Study on the use of nanostring nCounter to analyze RNA extracted from formalin-fixed-paraffin-embedded and fresh frozen bladder cancer tissues. Cancer Genetics, 2022;268-269:137-143.
7. Jin Z, Zhang W, Liu H, Ding A, Lin Y, Wu SX, Lin J. Potential therapeutic application of local anesthetics in cancer treatment. Recent Patents on Anti-Cancer Drug Discovery, 2022;17(4):326-342.
8. Frank P, Batty GD, Pentti J, Jokela M, Poole L, Ervasti J, Vahtera J, Lewis G, Steptoe A, Kivimäki M. Association between depression and physical conditions requiring hospitalization. JAMA Psychiatry, 2023;80(7):690-699.
9. Indirli R, Lanzi V, Arosio M, Mantovani G, Ferrante E. The association of hypogonadism with depression and its treatments. Frontiers in Endocrinology, 2023;14:1198437(1-14).
10. Steffens DC. Treatment-resistant depression in older adults. The New England Journal of Medicine, 2024;390(7):630-639.
11. Lorenzo EC, Kuchel GA, Kuo CL, Moffitt TE, Diniz BS. Major depression and the biological hallmarks of aging. Ageing Research Reviews, 2023;83:101805(1-27).
12. Mirchandaney R, Barete R, Asarnow LD. Moderators of cognitive behavioral treatment for insomnia on depression and anxiety outcomes. Current Psychiatry Reports, 2022;24(2):121-128.
13. Heissel A, Heinen D, Brokmeier LL, Skarabis N, Kangas M, Vancampfort D, Stubbs B, Firth J, Ward PB, Rosenbaum S, Hallgren M, Schuch F. Exercise as medicine for depressive symptoms? A systematic review and meta-analysis with meta-regression. British Journal of Sports Medicine 57(Pt A):bjsports-2022-106282, 2023;57(16):1049-1057.
14. Kofod J, Elfving B, Nielsen EH, Mors O, Köhler-Forsberg O. Depression and inflammation: correlation between changes in inflammatory markers with antidepressant response and long-term prognosis. European Neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 2022;54:116-125.
15. Runia N, Yücel DE, Lok A, de Jong K, Denys DAJP, van Wingen GA, Bergfeld IO. The neurobiology of treatment-resistant depression: A systematic review of neuroimaging studies. Neuroscience and Biobehavioral Reviews, 2022;132:433-448.
16. Hagatulah N, Bränn E, Oberg AS, Valdimarsdóttir UA, Shen Q, Lu D. Perinatal depression and risk of mortality: nationwide, register based study in Sweden. BMJ, 2024;384:e075462(1-10).
17. Vita G, Compri B, Matcham F, Barbui C, Ostuzzi G. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2023 Mar 31;3(3):CD011006(1-80).
18. Mitra A, Raichle ME, Geoly AD, Kratter IH, Williams NR. Targeted neurostimulation reverses a spatiotemporal biomarker of treatment-resistant depression. Proceedings of the National Academy of Sciences of the United States of America, 2023;120(21):e2218958120(1-6).
19. Siddiqi SH, Kandala S, Hacker CD, Bouchard H, Leuthardt EC, Corbetta M, Morey RA, Brody DL. Precision functional MRI mapping reveals distinct connectivity patterns for depression associated with traumatic brain injury. Science Translational Medicine, 2023;15(703):eabn0441(1-11).
20. Maruani J, Boiret C, Leseur J, Romier A, Bazin B, Stern E, Lejoyeux M, Geoffroy PA. Major depressive episode with insomnia and excessive daytime sleepiness: a more homogeneous and severe subtype of depression. Psychiatry Research, 2023;330:115603(1-8).
21. Currie JM, Mercer M, Michael R, Pichardo D. New caregiver diagnoses of severe depression and child asthma controller medication adherence. International Journal of Environmental Research and Public Health, 2023;20(11):5986(1-10).
22. Zwolińska W, Skibinska M, Słopień A, Dmitrzak-Węglarz M. ProBDNF as an indicator of improvement among women with depressive episodes. Metabolites, 2022;12(4):358(1-9).
23. Sochal M, Ditmer M, Binienda A, Gabryelska A, Białasiewicz P, Talar-Wojnarowska R, Fichna J, Małecka-Wojciesko E. Relation between selected sleep parameters, depression, anti-tumor necrosis factor therapy, and the brain-derived neurotrophic factor pathway in inflammatory bowel disease. Metabolites, 2023;13(3):450(1-18).
24. Min X, Wang G, Cui Y, Meng P, Hu X, Liu S, Wang Y. Association between inflammatory cytokines and symptoms of major depressive disorder in adults. Frontiers in Immunology, 2023;14:1110775(1-8).
Objavljeno
2025/01/16
Broj časopisa
Rubrika
Original paper
Sva prava zadržana (c) 2025 Ya Gao
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.